undermined by their immunogenicity and the development of anti-drug antibodies (ADA) associated with treatment failure and hypersensitivity reactions 2 . Methotrexate (MTX) has been shown to reduce the generation of an ADA response 3 . The ability of other conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) to mitigate unwanted immunogenicity, and prolong efficacy in patients who cannot tolerate methotrexate, is less clear. Objectives: We previously reported that MTX markedly inhibited the production and release of soluble immunoglobulin (sIgG) by human primary B cells cocultured with PBMC (BT system) in the in vitro BioMAP ® phenotypic screening panel 4,5 . MTX also had anti-proliferative effects on human primary tissue and immune cell types 6 . We evaluated other csDMARDs to determine if they were broadly active or, were more similar to MTX in selectively blocking sIgG production and therefore would be more likely to reduce ADA associated with biologics. Methods: A series of csDMARDS (sulfasalazine, hydroxychloroquine, cyclosporine, leflunomide and azathioprine) were profiled at 4 concentrations across the BioMAP Diversity PLUS™ panel to generate phenotypic activity profiles. In addition to assessing sIgG production, effects on a broad scope of disease-relevant readouts related to primary cell activation and proliferation, inflammation, wound healing, tissue/matrix remodeling, and fibrosis were also evaluated. Results: Similar to MTX, cyclosporine, leflunomide and azathioprine strongly inhibited sIgG production at all tested concentrations. In contrast, treatment with sulfasalazine or hydroxychloroquine did not decrease sIgG indicating these compounds may not mitigate the immunogenicicty of biologics. In contrast to MTX, several csDMARDS were broadly active in many BioMAP systems. Bioinformatics analysis was used to identify distinct mechanistic signatures for these agents in the BioMAP Panel.
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Conclusions:
These results support application of the BioMAP in vitro assay systems, widely utilized for preclinical drug discovery, to determine the suitability of csDMARDS as anti-immunogenic co-treatments to extend the clinical efficacy of biologics. Clinical studies are needed to confirm these results, however, in inflammatory bowel diseases and to a less extent in rheumatoid arthritis, azathioprine has been shown to reduce immunogenicity of biologics 7 . References: Background: Methotrexate (MTX) is the DMARD of first choice in the treatment of rheumatoid arthritis (RA). Objectives: To investigate the clinical characteristics and describe therapeutic approaches in RA patients ongoing MTX not achieving a DAS28 "low disease activity" score.
THU0181 CLINICAL CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENTS ONGOING METHOTREXATE THERAPY NOT ACHIEVING DAS28 "LOW DISEASES ACTIVITY": A MATCHED CASE-CONTROL ANALYSIS FROM THE MARI STUDY
Methods: This is a case-control analysis including 186 patients (mean age±SD, 61±12 years, 16% males) who did not achieve a DAS28 "low disease activity" score (defined by a value ≤3.2) and 558 age-and gender-frequency-matched (1:3), randomly selected controls (mean age age±SD, 61±13 years) who achieved a DAS28 "low disease activity" from the original cohort investigated in the MARI study. The MARI study enrolled RA patients on treatment for at least 12-month with MTX. Demographic, clinical, laboratory and pharmacological characteristics of patients recorded at baseline visit were considered for the current analysis. Background: Janus kinases (JAKs) are key proteins in the signal transduction of many cytokines and growth factors. The selective JAK1 inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study (DARWIN 2) as monotherapy in active rheumatoid arthritis (RA) patients with inadequate response to methotrexate and has shown a good safety and efficacy profile 1 . Objectives: To gain insight into filgotinib mode of action as monotherapy in RA patients by analysing the impact of filgotinib on a broad panel of immune modulators in the serum. Methods: RA patients received either placebo (PBO), or filgotinib monotherapy at 50mg, 100mg or 200mg once daily (QD). Serum samples were collected at baseline, week 4 and week 12 and analysed using the 18-plex bead-based immunoassay (HSTCMAG-28SK Merck-Millipore) on BioPLEX-200 instrument to measure cytokine concentration. Median % change from baseline for biomarkers are reported for week 4 and 12. Wilcoxon rank-sum test assessed the significance of difference between filgotinib treated groups and PBO. Results: Following treatment with filgotinib at 100 mg QD and 200mg QD, there were significant reductions in cytokines important in expansion and activity of multiple T cell subsets and innate immunity compared to PBO (see Table) . These changes include decreases in proinflammatory cytokines (IL-6, IL-1β, and TNFα), T H 1-related (IL-2, IFN-γ and IL-12), T H 2-related (IL-4, IL-5, and IL-13) and T H 17-related cytokines (IL-1β, IL-6, IL-17A, IL-21 and IL-23). All doses of 
